• ¿øÀڷº´¿ø
  • Áø·áÇù·Â¼¾ÅÍ
  • Home
  • ·Î±×ÀÎ
  • ȸ¿ø°¡ÀÔ
  • Sitemap
  • ¿øÀڷº´¿ø
ÅëÇÕ°Ë»ö
¼Ò½ÄÁ¤º¸
  • Çà»ç¾È³»
  • ¾ð·Ðº¸µµ
  • °øÁö»çÇ×
  • ÀÚ·á½Ç

ÇмúÇà»ç

Home > ¼Ò½ÄÁ¤º¸ > ÇмúÇà»ç
ÇмúÇà»ç¸ñ·Ï º¸±â
Á¦¸ñ Çѱ¹¿øÀÚ·ÂÀÇÇпø ÀÓ»ó0»ó ±¹Á¦ °øµ¿ ½ÉÆ÷Áö¾ö : ¸¶ÀÌÅ©·ÎµµÂ¡ ÀÓ»ó½ÃÇè ÀçÆí
µî·ÏÀÏ 2019-11-14 Á¶È¸¼ö 4602
³»¿ë

Çѱ¹¿øÀÚ·ÂÀÇÇпø ÀÓ»ó0»ó ±¹Á¦ °øµ¿ ½ÉÆ÷Áö¾ö

¿øÀڷº´¿ø ¹æ»ç¼±ÀÇÇÐÀӻ󿬱¸ºÎ¿¡¼­´Â ±¹³» ¿Ü Àü¹®°¡¸¦ ÃʺùÇÏ¿© ¸¶ÀÌÅ©·ÎµµÂ¡ Àӻ󿬱¸ÀÇ Çмú±³·ù ¹× ¿¬±¸Çù·Â ³×Æ®¿öÅ© °­È­¸¦ À§ÇÏ¿© ´ÙÀ½°ú °°ÀÌ ±¹Á¦ °øµ¿ ½ÉÆ÷Áö¾öÀ» °³ÃÖÇϰíÀÚ ÇÏ¿À´Ï °ü°èÀںеéÀÇ ¸¹Àº °ü½É°ú Âü¼® ºÎʵ右´Ï´Ù.

<Çѱ¹¿øÀÚ·ÂÀÇÇпø ÀÓ»ó0»ó ±¹Á¦ °øµ¿ ½ÉÆ÷Áö¾ö : ¸¶ÀÌÅ©·Î µµÂ¡ ÀÓ»ó½ÃÇè ÀçÆí>
(KIRAMS International Symposium on The Phase 0 Concept Reforming Cddnical Development Microdosing)

ÀÏ Á¤

1) 2019.12.2. (¿ù) 12:50 ~ 18:30 - Ãʺù ¿¬ÀÚ ¹ßÇ¥ µî ½ÉÆ÷Áö¾ö

2) 2019.12.3. (È­) 10:30 ~ 12:30 - Åä·Ðȸ(PET ¿µ»ó, ¸¶ÀÌÅ©·ÎµµÂ¡ÀÇ ¹Ì·¡¿Í CMC°ü·Ã Áú¹®¿¡ ´ëÇÑ ÁÖÁ¦Åä·Ð)

Àå ¼Ò

Çѱ¹¿øÀÚ·ÂÀÇÇпø ±¹°¡ RI½Å¾à¼¾ÅÍ ´ë°­´ç(5Ãþ)

ÁÖ ÃÖ

Çѱ¹¿øÀÚ·ÂÀÇÇпø ½Å°³³ä Ä¡·á ±â¼ú°³¹ß Ç÷§Æû ±¸Ãà»ç¾÷´Ü, ¿øÀڷº´¿ø ¹æ»ç¼±ÀÇÇÐ Àӻ󿬱¸ºÎ

ÃÊû¿¬ÀÚ

Ad Roffel, Ph.D. Director of Scientific Affairs / Clinical Pharmacology, PRA Health Sciences

Arjen Akkermann, MSc, PharmD, Senior Director CMC and Qualified Person - Early Developmental Services, PRA Health Sciences

±è¾ðÇý, M.D. Ph.D. ºÐ´çÂ÷º´¿ø ÀÓ»ó¾à¸®Çаú Á¶±³¼ö

Stephen Dueker, Ph.D. International AMS expert and Entrepreneur

Oliver Langer, PharmD, Ph.D. Senior Scientist at AIT Austrian Institute of Technology GmbH

Martin Bauer, M.D. Assoc Prof. Dept. Clinical Pharmacology, Univ. of Vienna

ÀÓÀÏÇÑ, M.D. Ph.D. ¿øÀڷº´¿ø ÇÙÀÇÇаú °úÀå

Âü°¡ºñ ¹«·á
 
»çÀüµî·Ï : ~2019.11.28(¸ñ) 17:00
 
¼¼ºÎ³»¿ë : ÷ºÎÆÄÀÏ ÂüÁ¶
 
¹®ÀÇ

Çѱ¹¿øÀÚ·ÂÀÇÇпø Ç÷§Æû±¸Ãà»ç¾÷´Ü »ç¾÷°ü¸®ÆÀ (Tel.02-970-8908 / 8910)

÷ºÎ ÷ºÎ 191202 Çà»çÆ÷½ºÅÍ_ÀÓ»ó0»ó ±¹Á¦°øµ¿½ÉÆ÷Áö¾ö(12.2-3).pdf
¸ñ·Ï
  • Çѱ¹¿øÀÚ·ÂÀÇÇпø
  • °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§
  • À̸ÞÀÏÁÖ¼Ò ¹«´Ü¼öÁý°ÅºÎ
ÁÖ¼Ò : (¿ì) 01812 ¼­¿ï½Ã ³ë¿ø±¸ °ø¸ªµ¿ 215-4 rc@kirams.re.kr ÀüÈ­ 02-970-1990~1 ÆÑ½º 02-970-2426
¿øÀڷº´¿ø